We previously reported that cyclin D1 silencing interferes with RAD51 accumulation and increases the sensitivity of BRCA1 wild-type ovarian cancer cells to olaparib. However, the mechanisms associated with cyclin D1 overexpression in ovarian cancer are not fully understood. TargetScan predicted the potential binding sites for microRNA-20b (miR-20b) and the 3′-untranslated region of cyclin D1 mRNA; thus, we used luciferase reporter assay to verify those binding sites. The Kaplan-Meier method and log-rank test were used to examine the relationship between miR-20b and progression-free survival of ovarian cancer patients in The Cancer Genome Atlas (n = 367) dataset. In vitro experiments were performed to evaluate the effects of miR-20b on cyclin D1 expression, cell cycle and response to olaparib. A peritoneal cavity metastasis model of ovarian cancer was established to determine the effect of miR-20b on the sensitivity of olaparib. Immunohistochemistry was performed to evaluate molecular mechanisms. In this work, we demonstrated that miR-20b down-regulates cyclin D1, increases the sensitivity of ovarian cancer cells to olaparib, reduces the expression of RAD51, and induces cell cycle arrest in G0/G1 phase. Ovarian cancer patients with higher expression of miR-20b had significantly longer progression-free survival. These results indicate that miR-20b may be a potential clinical indicator for the sensitivity of ovarian cancer to olaparib and the survival of ovarian cancer patients. Our findings suggest that miR-20b may have therapeutic value in combination with olaparib treatment for ovarian cancer.
ZhongQWenYJYangHSLuoHFuAFYangFChenLJChenXQiXRLinHGWanYChenXCWeiYQZhaoX.Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice. Ann Oncol2008;
19:1584–91
2.
KimGIsonGMcKeeAEZhangHTangSGwiseTSridharaRLeeETzouAPhilipRChiuHJRicksTKPalmbyTRussellAMLadouceurGPfumaELiHZhaoLLiuQVenugopalRIbrahimAPazdurR.FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-Mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res2015;
21:4257–61
3.
JaspersJEKersbergenABoonUSolWvan DeemterLZanderSADrostRWientjensEJiJAlyADoroshowJHCranstonAMartinNMLauAO'ConnorMJGanesanSBorstPJonkersJRottenbergS.Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov2013;
3:68–81
4.
XuGChapmanJRBrandsmaIYuanJMistrikMBouwmanPBartkovaJGogolaEWarmerdamDBarazasMJaspersJEWatanabeKPieterseMKersbergenASolWCeliePHNSchoutenPCvan den BroekBSalmanANieuwlandMde RinkIde RondeJJalinkKBoultonSJChenJvan GentDCBartekJJonkersJBorstPRottenbergS.REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature2015;
521:541–4
5.
Ray ChaudhuriACallenEDingXGogolaEDuarteAALeeJEWongNLafargaVCalvoJAPanzarinoNJJohnSDayACrespoAVShenBStarnesLMde RuiterJRDanielJAKonstantinopoulosPACortezDCantorSBFernandez-CapetilloOGeKJonkersJRottenbergSSharanSKNussenzweigA.Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature2016;
535:382–7
6.
LiuJMatulonisUA.New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin Cancer Res2014;
20:5150–6
7.
YangLZhangYShanWHuZYuanJPiJWangYFanLTangZLiCHuXTanyiJLFanYHuangQMontoneKDangCVZhangL.Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med2017;
9.
KonstantinopoulosPACeccaldiRShapiroGID'AndreaAD.Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov2015;
5:1137–54
10.
10. Erratum for the Perspective: “Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action” by Y. Pommier, M. J. O'Connor, J. de Bono. Sci Transl Med2016;8:368er7
11.
ZhongQHuZLiQYiTLiJYangH.Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib. Gynecol Oncol2019;
152:157–65
12.
BaggaSBrachtJHunterSMassirerKHoltzJEachusRPasquinelliAE.Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell2005;
122:553–63
13.
RupaimooleRSlackFJ.MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov2017;
16:203–22
14.
StordalBTimmsKFarrellyAGallagherDBusschotsSRenaudMTheryJWilliamsDPotterJTranTKorpantyGCremonaMCareyMLiJLiYAslanOO'LearyJJMillsGBHennessyBT.BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol2013;
7:567–79
15.
BaiYDengHYangYZhaoXWeiYXieGLiZChenXChenLWangYSuDQianZZhongQLuoHYiT.VEGF-targeted short hairpin RNA inhibits intraperitoneal ovarian cancer growth in nude mice. Oncology2009;
77:385–94
16.
RottenbergSJaspersJEKersbergenAvan der BurgENygrenAOZanderSADerksenPWde BruinMZevenhovenJLauABoulterRCranstonAO'ConnorMJMartinNMBorstPJonkersJ.High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA2008;
105:17079–84
17.
JelinicPLevineDA.New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair. Mol Cancer Ther2014;
13:1645–54
18.
ZhaoWSteinfeldJBLiangFChenXMaranonDGJian MaCKwonYRaoTWangWShengCSongXDengYJimenez-SainzJLuLJensenRBXiongYKupferGMWieseCGreeneECSungP.BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature2017;
550:360–5
19.
YangZWaldmanASWyattMD.Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. Biochem Pharmacol2012;
83:741–6
20.
KuoLJYangLX.Gamma-H2AX – a novel biomarker for DNA double-strand breaks. In Vivo2008;
22:305–9.
21.
Cancer Genome Atlas Research N.Integrated genomic analyses of ovarian carcinoma. Nature2011;
474:609–15
22.
FongPCYapTABossDSCardenCPMergui-RoelvinkMGourleyCDe GreveJLubinskiJShanleySMessiouCA'HernRTuttAAshworthAStoneJCarmichaelJSchellensJHde BonoJSKayeSB.Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol2010;
28:2512–9
23.
DaiJWeiRJLiRFengJBYuYLLiuPS.A study of CCND1 with epithelial ovarian cancer cell proliferation and apoptosis. Eur Rev Med Pharmacol Sci2016;
20:4230–5
24.
BaliAO'BrienPMEdwardsLSSutherlandRLHackerNFHenshallSM.Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res2004;
10:5168–77
25.
JirawatnotaiSHuYMichowskiWEliasJEBecksLBienvenuFZagozdzonAGoswamiTWangYEClarkABKunkelTAvan HarnTXiaBCorrellMQuackenbushJLivingstonDMGygiSPSicinskiP.A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature2011;
474:230–4
26.
CrosbyMEKulshreshthaRIvanMGlazerPM.MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res2009;
69:1221–9
27.
WangYHuangJWCalsesPKempCJTaniguchiT.MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res2012;
72:4037–46
28.
LalAPanYNavarroFDykxhoornDMMoreauLMeireEBentwichZLiebermanJChowdhuryD.miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat Struct Mol Biol2009;
16:492–8
29.
WangYHuangJWLiMCaveneeWKMitchellPSZhouXTewariMFurnariFBTaniguchiT.MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol Cancer Res2011;
9:1100–11
30.
HuHDuLNagabayashiGSeegerRCGattiRA.ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci U S A2010;
107:1506–11
31.
YangNKaurSVoliniaSGreshockJLassusHHasegawaKLiangSLeminenADengSSmithLJohnstoneCNChenXMLiuCGHuangQKatsarosDCalinGAWeberBLButzowRCroceCMCoukosGZhangL.MicroRNA microarray identifies let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res2008;
68:10307–14
32.
CaiJYangCYangQDingHJiaJGuoJWangJWangZ.Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis2013;
2:e75
33.
TanzerAStadlerPF.Molecular evolution of a microRNA cluster. J Mol Biol2004;
339:327–35
34.
AoXNiePWuBXuWZhangTWangSChangHZouZ.Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Cell Death Dis2016;
7:e2463
35.
ZhangYGuanDHBiRXXieJYangCHJiangYH.Prognostic value of microRNAs in gastric cancer: a meta-analysis. Oncotarget2017;
8:55489–510
36.
LiCQinFHuFXuHSunGHanGWangTGuoM.Characterization and selective incorporation of small non-coding RNAs in non-small cell lung cancer extracellular vesicles. Cell Biosci2018;
8:2
37.
GuoJXiaoZYuXCaoR.miR-20b promotes cellular proliferation and migration by directly regulating phosphatase and tensin homolog in prostate cancer. Oncol Lett2017;
14:6895–900
38.
ParkSLChoTMWonSYSongJHNohDHKimWJMoonSK.MicroRNA-20b inhibits the proliferation, migration and invasion of bladder cancer EJ cells via the targeting of cell cycle regulation and Sp-1-mediated MMP-2 expression. Oncol Rep2015;
34:1605–12
39.
JiangZYinJFuWMoYPanYDaiLHuangHLiSZhaoJ.MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC. PloS One2014;
9:e94639
40.
HongSYuSLiJYinYLiuYZhangQGuanHLiYXiaoH.MiR-20b displays tumor-suppressor functions in papillary thyroid carcinoma by regulating the MAPK/ERK signaling pathway. Thyroid2016;
26:1733–43
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
